Protective effect of omeprazole and lansoprazole on β-receptor stimulated myocardial infarction in Wistar rats

  • Ashwini S. Patil
  • Alok D. Singh
  • Umesh B. Mahajan
  • Chandragouda R. Patil
  • Shreesh Ojha
  • Sameer N. GoyalEmail author


We investigated the effect of omeprazole (OPZ) and lansoprazole (LPZ) on the pathophysiology of myocardial necrosis in rats by inspecting a series of indicators like hemodynamic parameters, biochemical estimations and histopathological changes in the myocardial tissue. Rats received either OPZ, LPZ (50 mg/kg/day, p.o.) individually for 7 days with concurrent administration of isoproterenol (ISO) (150 mg/kg, s.c.) on 6th and 7th day of study period to induce myocardial infarction. On the 8th day after measuring hemodynamic parameters, rats were killed and parameters were evaluated. ECG waves were found to be normal in the treatment group. ISO control rats revealed escalation in the oxidative stress as evidenced by depletion in the content of SOD, GSH, catalase and increase in the level of MDA and NO as compared with the normal rats. Treatment with OPZ and LPZ significantly reduced the ROS, indicated by an increase in the endogenous antioxidants and a decrease in NO and MDA levels. ISO control rats showed a significant elevation in the levels of pro-inflammatory cytokine TNF-α as compared to the normal and treatment group of rats. Administration of OPZ and LPZ does not exhibit any significant toxicity. Our findings reveal that multiple doses of OPZ and LPZ may have distinctly minimized the ISO-induced myocardial necrosis by declining the hmodynamic parameters, oxidative stress and pro-inflammatory cytokine TNF-α in myocardial infarcted rats.


Myocardial infarction Omeprazole Lansoprazole ROS Cytokines 



The authors also acknowledge the financial support received under Early Career Research Award Scheme (File No. ECR/2016/001243) of Science and Engineering Research Board (SERB), Department of Science and Technology, New Delhi, India.

Compliance with ethical standards

Conflict of interest

The authors declare that there are no conflicts of interest.

Ethical approval

The study protocol used in the study was approved by the Institutional Animal Ethics Committee (Approval No. IAEC/RCPIPER/2017-18/13) of R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, India. The animals were preserved, and inventive procedures were carried out in accordance with the guideline laid down by Committee for the Purpose of Control and Supervision of the Experiments on Animals (CPCSEA) composed under the Prevention of the Cruelty to Animals Act, 1960, Ministry of Environment and Forests, Government of India (Reg. No. IAEC/RCPIPER/2017-18/13).


  1. 1.
    Lobo Filho HG, Ferreira NL, Sousa RBd, Carvalho ERd, Lobo PLD, Lobo Filho JG (2011) Experimental model of myocardial infarction induced by isoproterenol in rats. Braz J Cardiovasc Surg 26:469–476CrossRefGoogle Scholar
  2. 2.
    Liu YT, Zhou C, Jia HM, Chang X, Zou ZM (2016) Standardized Chinese Formula Xin-Ke-Shu inhibits the myocardium Ca2 overloading and metabolic alternations in isoproterenol-induced myocardial infarction rats. Sci Rep 26(6):30208CrossRefGoogle Scholar
  3. 3.
    Khan V, Sharma S, Bhandari U, Ali SM, Haque SE (2018) Raspberry ketone protects against isoproterenol-induced myocardial infarction in rats. Life Sci 194:205–212CrossRefGoogle Scholar
  4. 4.
    Oikonomou E, Mourouzis K, Fountoulakis P, Papamikroulis GA, Siasos G, Antonopoulos A, Vogiatzi G, Tsalamadris S, Vavuranakis M, Tousoulis D (2018) Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance. Heart Fail Rev 23:389–408CrossRefGoogle Scholar
  5. 5.
    Nakahara K, Fujiwara Y, Tsukahara T, Yamagami H, Tanigawa T, Shiba M, Tominaga K, Watanabe T, Urade Y, Arakawa T (2014) Acid reflux directly causes sleep disturbances in rat with chronic esophagitis. PLoS ONE 9:e106969CrossRefGoogle Scholar
  6. 6.
    Biswas K, Bandyopadhyay U, Chattopadhyay I, Varadaraj A, Ali E, Banerjee RK (2003) A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem 278:10993–11001CrossRefGoogle Scholar
  7. 7.
    Chanchal SK, Mahajan UB, Siddharth S, Reddy N, Goyal SN, Patil PH, Bommanahalli BP, Kundu CN, Patil CR, Ojha S (2016) In vivo and in vitro protective effects of omeprazole against neuropathic pain. Sci Rep 6:30007CrossRefGoogle Scholar
  8. 8.
    Patlolla JM, Zhang Y, Li Q, Steele VE, Rao CV (2012) Anti-carcinogenic properties of omeprazole against human colon cancer cells and azoxymethane-induced colonic aberrant crypt foci formation in rats. Int J Oncol 40:170–175Google Scholar
  9. 9.
    Yates TA, Tomlinson LA, Bhaskaran K, Langan S, Thomas S, Smeeth L, Douglas IJ (2017) Lansoprazole use and tuberculosis incidence in the United Kingdom Clinical Practice Research Datalink: a population based cohort. PLoS Med 14:e1002457CrossRefGoogle Scholar
  10. 10.
    Neiger R, Gaschen F, Jaggy A (2000) Gastric mucosal lesions in dogs with acute intervertebral disc disease: characterization and effects of omeprazole or misoprostol. J Vet Intern Med 14:33–36CrossRefGoogle Scholar
  11. 11.
    Goyal SN, Sharma C, Mahajan UB, Patil CR, Agrawal YO, Kumari S, Arya DS, Ojha S (2015) Protective effects of cardamom in isoproterenol-induced myocardial infarction in rats. Int J Mol Sci 16:27457–27469CrossRefGoogle Scholar
  12. 12.
    Mahajan UB, Patil PD, Chandrayan G, Patil CR, Agrawal YO, Ojha S, Goyal SN (2018) Eplerenone pretreatment protects the myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats. Mole Cell Biochem 446(1–2):91–103CrossRefGoogle Scholar
  13. 13.
    Mert H, Yılmaz H, Irak K, Yıldırım S, Mert N (2018) Investigation of the protective effect of Kefir against isoproterenol induced myocardial infarction in rats. Korean J Food Sci Anim Resour 38(2):259–272Google Scholar
  14. 14.
    Sonawane VK, Mahajan UB, Shinde SD, Chatterjee S, Chaudhari SS, Bhangale HA, Ojha S, Goyal SN, Kundu CN, Patil CR (2018) A chemosensitizer drug: Disulfiram prevents doxorubicin-induced cardiac dysfunction and oxidative stress in rats. Cardiovasc Toxicol 18(5):459–470CrossRefGoogle Scholar
  15. 15.
    Mahajan UB, Chandrayan G, Patil CR, Arya DS, Suchal K, Agrawal YO, Ojha S, Goyal SN (2017) The protective effect of apigenin on myocardial injury in diabetic rats mediating activation of the PPAR-γ pathway. Int J Mol Sci 18:756CrossRefGoogle Scholar
  16. 16.
    Reddy NM, Mahajan UB, Patil CR, Agrawal YO, Ojha S, Goyal SN (2015) Eplerenone attenuates cardiac dysfunction and oxidative stress in β-receptor stimulated myocardial infarcted rats. Am J Transl Res 15(9):1602–1611 7(Google Scholar
  17. 17.
    Goyal SN, Sharma C, Mahajan UB, Patil CR, Agrawal YO, Kumari S, Arya DS, Ojha S (2015) Protective effects of cardamom in isoproterenol-induced myocardial infarction in rats. Int J Mol Sci 16(11):27457–27469CrossRefGoogle Scholar
  18. 18.
    Padmanabhan M, Rajadurai M, Prince PSM (2008) Preventive effect of S-allylcysteine on membrane-bound enzymes and glycoproteins in normal and Isoproterenol-induced cardiac toxicity in male Wistar rats. Basic Clin Pharmacol Toxicol 103:507–513CrossRefGoogle Scholar
  19. 19.
    Hill R, Howard A, Gresham G (1960) The electrocardiographic appearances of myocardial infarction in the rat. Br J Exp Pathol 41:633–637Google Scholar
  20. 20.
    Ghoneim MA, Hassan AI, Mahmoud MG, Asker MS (2016) Protective effect of adansonia digitata against isoproterenol-induced myocardial injury in rats. Anim Biotechnol 27:84–95CrossRefGoogle Scholar
  21. 21.
    Phaniendra A, Jestadi DB, Periyasamy L (2014) Free radicals: properties, sources, targets, and their implication in various diseases. Indian J Clin Biochem 30(1):11–26CrossRefGoogle Scholar
  22. 22.
    Nagoor Meeran MF, Jagadeesh GS, Selvaraj P (2015) Thymol attenuates inflammation in isoproterenol induced myocardial infarcted rats by inhibiting the release of lysosomal enzymes and downregulating the expressions of proinflammatory cytokines. Eur J Pharmacol 5(754):153–161CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Ashwini S. Patil
    • 1
  • Alok D. Singh
    • 1
  • Umesh B. Mahajan
    • 1
  • Chandragouda R. Patil
    • 1
  • Shreesh Ojha
    • 2
  • Sameer N. Goyal
    • 1
    • 3
    Email author
  1. 1.Department of PharmacologyR. C. Patel Institute of Pharmaceutical Education and ResearchShirpurIndia
  2. 2.Department of Pharmacology and Therapeutics, College of Medicine and Health SciencesUnited Arab Emirates UniversityAl Ain, Abu DhabiUAE
  3. 3.Shri Vile Parle Kelavani Mandal’s Institute of PharmacyDhuleIndia

Personalised recommendations